- Dec 11, 2019

Immunotherapy drug improves outcomes for some children with relapsed leukemia

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

Fusion oncoprotein forces cell fates toward rhabdomyosarcoma

“DNA loops” in pediatric brain tumors double relapse risk

Radiation from a childhood CT scan increases the risk of developing cancer

Childhood Leukemia Linked to Pesticides Used in Vineyards

FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma

NIH researchers develop approach that could help supercharge T-cell therapies against solid tumors

Cranial Radiotherapy Predisposes Pediatric Cancer Survivors to Hypothyroidism

Examining outcomes in children with Down syndrome and acute lymphoblastic leukemia

Impact of childhood and adolescence cancer on family caregivers

Collaborative study identifies potential targets to treat the most common childhood liver cancer

Recent Posts

Immunotherapy drug improves outcomes for some children with relapsed leukemia

Archive

Search By Tags